Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Absolute bioavailability and pharmacokinetic study of velusetrag in healthy adults
NL-OMON59055Phase 1Completed
- Sponsor
- Alfasigma
- Start
- Oct 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of velusetrag in chronic intestinal pseudo-obstruction (CIPO) (2 arms), sponsored by Alfasigma. Primary endpoint: Primary endpoint(s). Started Oct 2024; status: completed.
02
Drugs
velusetrag
03
Conditions
chronic intestinal pseudo-obstruction (CIPO)
Beyond the preview
Go deeper on NL-OMON59055.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON59055.